{"id":62402,"date":"2025-12-24T01:05:56","date_gmt":"2025-12-24T00:05:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/"},"modified":"2025-12-24T01:05:56","modified_gmt":"2025-12-24T00:05:56","slug":"janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/","title":{"rendered":"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today provided a program update on its ongoing Phase 1 study evaluating JANX008, its EGFR-targeted TRACTr, in multiple solid tumor indications.<\/p>\n

<\/a>
<\/a><\/p>\n

\nJANX008 is being evaluated in an ongoing Phase 1 study (NCT05783622) designed to assess safety, pharmacokinetics\/pharmacodynamics, and evidence of clinical activity. The Phase 1a dose-escalation portion of the study has been completed, and the program has initiated expansion cohorts to enable further evaluation and support continued dose optimization across selected solid tumor settings.<\/p>\n

\nJanux expects to provide additional updates on JANX008 as the study progresses and data continue to mature.<\/p>\n

\nJanux\u2019s TRACTr, TRACIr and ARM Pipeline<\/b><\/p>\n

\nJanux\u2019s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux\u2019s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. Janux is also advancing additional CD3-based TRACTr and CD28-based TRACIr programs for future clinical development, including a PSMA-TRACIr for use in combination with our PSMA-TRACTr JANX007, and a TROP2-TRACTr for the treatment of TROP2+ solid tumors. Janux is advancing its first ARM platform program candidate, a CD19-ARM for the potential treatment of autoimmune diseases toward clinical trials. Janux is also generating a number of additional TRACTr, TRACIr and ARM programs for potential future development.<\/p>\n

\nAbout Janux Therapeutics<\/b><\/p>\n

\nJanux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com<\/a> and follow us on LinkedIn.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux\u2019s ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux\u2019s development activities, including its ongoing and planned preclinical studies and clinical trials, the potential benefits of Janux\u2019s product candidates and platform technologies, and expectations regarding the use of Janux\u2019s platform technologies to generate novel product candidates. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and\/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cpromise,\u201d \u201cpotential,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201ccontinues,\u201d \u201cdesigned,\u201d \u201cgoal,\u201d or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux\u2019s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov<\/a>. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Chad Rubin
\n
Endurance Advisors
\n
crubin@enduranceadvisors.com<\/a>
646.319.3261<\/p>\n

\nMedia:<\/b>
Jessica Yingling, Ph.D.
\n
Little Dog Communications Inc.
\n
jessica@litldog.com<\/a>
858.344.8091<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today provided a program update on its ongoing Phase 1 study evaluating JANX008, its EGFR-targeted … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62402","6":"format-standard","7":"category-industry"},"yoast_head":"\nJanux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today provided a program update on its ongoing Phase 1 study evaluating JANX008, its EGFR-targeted ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-24T00:05:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251223806068\/en\/1538478\/22\/janux-logo-web_page_01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study\",\"datePublished\":\"2025-12-24T00:05:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/\"},\"wordCount\":871,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251223806068\\\/en\\\/1538478\\\/22\\\/janux-logo-web_page_01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/\",\"name\":\"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251223806068\\\/en\\\/1538478\\\/22\\\/janux-logo-web_page_01.jpg\",\"datePublished\":\"2025-12-24T00:05:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251223806068\\\/en\\\/1538478\\\/22\\\/janux-logo-web_page_01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251223806068\\\/en\\\/1538478\\\/22\\\/janux-logo-web_page_01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/","og_locale":"en_US","og_type":"article","og_title":"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today provided a program update on its ongoing Phase 1 study evaluating JANX008, its EGFR-targeted ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-24T00:05:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251223806068\/en\/1538478\/22\/janux-logo-web_page_01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study","datePublished":"2025-12-24T00:05:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/"},"wordCount":871,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251223806068\/en\/1538478\/22\/janux-logo-web_page_01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/","url":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/","name":"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251223806068\/en\/1538478\/22\/janux-logo-web_page_01.jpg","datePublished":"2025-12-24T00:05:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251223806068\/en\/1538478\/22\/janux-logo-web_page_01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251223806068\/en\/1538478\/22\/janux-logo-web_page_01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-provides-program-update-on-ongoing-phase-1-janx008-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62402"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62402\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}